News Releases

September 26, 2025

Merck Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple […]

August 18, 2025

Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will […]

July 10, 2025

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and […]

November 26, 2024

Merck Animal Health Announces European Approval of BRAVECTO® TriUNO for Use in Dogs

The new formulation targets internal and external parasites, expanding the BRAVECTO® portfolio RAHWAY, N.J., November 26, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for […]

January 29, 2024

European Commission Approves Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs

Rahway, NJ., January 29, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the European Commission (EC) has approved BRAVECTO® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The product […]